1
|
Hajibeygi R, Mirghazanfari SM, Pahlavani N, Jalil AT, Alshahrani SH, Rizaev JA, Hadi S, Hadi V, Yekta NH. Effect of a diet based on Iranian traditional medicine on inflammatory markers and clinical outcomes in COVID-19 patients: A double-blind, randomized, controlled trial. Eur J Integr Med 2022; 55:102179. [PMID: 36035633 PMCID: PMC9391229 DOI: 10.1016/j.eujim.2022.102179] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/20/2022] [Revised: 08/16/2022] [Accepted: 08/17/2022] [Indexed: 11/27/2022]
Abstract
Introduction SARS-CoV-2 causes severe acute respiratory syndrome prompting worldwide demand for new antiviral treatments and supportive care for organ failure caused by this life-threatening virus. This study aimed to help develop a new Traditional Persian Medicine (TPM) -based drug and assess its efficacy and safety in COVID-19 patients with major symptoms. Methods In February 2022, a randomized clinical trial was conducted among 160 patients with a confirmed diagnosis of COVID-19 admitted to Emam Reza (AJA) Hospital in Tehran, Iran. During their hospitalization, the intervention group received a treatment protocol approved by Iran's Ministry of Health and Medical Education (MOHME), consisting of an Iranian regimen, Ficus carica; Vitis vinifera, Safflower, Cicer arietinum, Descurainiasophia seeds, Ziziphus jujuba, chicken soup, barley soup, rose water, saffron, and cinnamon spices. All patients were compared in terms of demographics, clinical, and laboratory variables. Results One hundred and sixty COVID-19 patients were divided into two groups: intervention and control. In baseline characteristics, there was no significant difference between the intervention and control groups (p>0.05). Using SPSS software version 22, statistical analysis revealed a significant difference in four symptoms: myalgia, weakness, headache, and cough (p<0.05). During the 5-day treatment period, the control group had significantly lower C-reactive protein (p<0.05). Conclusion While more research with a larger sample size is needed, the proposed combination appears to be effective in the treatment of symptoms as well as inflammatory biomarkers such as C-reactive protein in COVID-19 patients. Iranian registry of clinical trials (IRCT) IRCT20220227054140N1.
Collapse
Key Words
- BMI, Body mass index
- C-reactive protein, CRP
- COVID-19, Traditional Persian Medicine, Ficus carica
- Cicer arietinum
- Fatigue Assessment Scale, FAS
- Intensive care unit, ICU
- Ministry of Health and Medical Education, MOHME
- Polymerase chain reaction, PCR
- Severe acute respiratory syndrome coronavirus 2, SARS-CoV-2
- Superoxide dismutase, SOD
- Traditional Persian Medicine, TPM
- Visual analog scale, VAS
- Vitis vinifera
- alanine aminotransferase, ALT
- aspartate aminotransferase, AST
- blood urea nitrogen, BUN
- creatinine, Cr
- hemoglobin, HB
- lactate dehydrogenase, LDH
- red blood cells, RBC
- white blood cells, WBC
Collapse
Affiliation(s)
- Ramtin Hajibeygi
- Department of Health, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
| | - Sayid Mahdi Mirghazanfari
- Department of Physiology and Iranian Medicine, School of Medicine, AJA University of Medical Sciences
| | - Naseh Pahlavani
- Health Sciences Research Center, Torbat Heydariyeh University of Medical Sciences, Torbat Heydariyeh, Iran
| | - Abduladheem Turki Jalil
- Medical Laboratories Techniques Department, Al-Mustaqbal University College, Babylon, Hilla, 51001, Iraq
| | | | - Jasur Alimdjanovich Rizaev
- Department of Public Health and Healthcare Management, Rector, Samarkand State Medical University, 18, Amir Temur Street, Samarkand, Uzbekistan
| | - Saeid Hadi
- Department of Health, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
| | - Vahid Hadi
- Department of Health, School of Medicine, AJA University of Medical Sciences, Tehran, Iran
| | - Nafiseh Hosseini Yekta
- Department of Persian Medicine, Faculty of Medicine, AJA University of Medical Sciences, Tehran, Iran
| |
Collapse
|
2
|
Li W, Zhang X, Ding M, Xin Y, Xuan Y, Zhao Y. Genotoxicity and subchronic toxicological study of a novel ginsenoside derivative 25-OCH 3-PPD in beagle dogs. J Ginseng Res 2019; 43:562-571. [PMID: 31700258 PMCID: PMC6823799 DOI: 10.1016/j.jgr.2018.05.005] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/27/2016] [Revised: 08/30/2017] [Accepted: 05/25/2018] [Indexed: 11/17/2022] Open
Abstract
Background Ginsenosides have been widely used clinically for many years and were regarded as very safe. However, a few researches on the toxicities of these kinds of agents showed that some ginsenosides may have side-effect on the rats or dogs. So it is extremely necessary to further clarify the potential toxicity of ginsenosides. This study was carried out to investigate long-term toxicity and genotoxicity of 25-methoxydammarane-3, 12, 20-triol (25-OCH3-PPD), a new derivative of ginsenoside, in beagle dogs. Methods Twenty-four beagle dogs were divided randomly into four treatment groups and repeatedly orally administered with 25-OCH3-PPD capsule at 60, 120, and 240 mg/kg/day for 91 consecutive days. Ames, micronucleus, and chromosomal aberration tests were established to analyze the possible genotoxicity of 25-OCH3-PPD. Results There was no 25-OCH3-PPD–induced systemic toxicity in beagle dogs at any doses. The level of 25-OCH3-PPD at which no adverse effects were observed was found to be 240 mg/kg/day. The result of Ames test showed that there was no significant increase in the number of revertant colonies of 25-OCH3-PPD administrated groups compared to the vehicle control group. There were also no significant differences between 25-OCH3-PPD administrated groups at all dose levels and negative group in the micronucleus test and chromosomal aberration assay. Conclusion The highest dose level of 25-OCH3-PPD at which no adverse effects were observed was found to be 240 mg/kg per day, and it is not a genotoxic agent either in somatic cells or germs cells. 25-OCH3-PPD is an extremely safe candidate compound for antitumor treatment.
Collapse
Key Words
- 25-OCH3-PPD, 25-methoxydammarane-3, 12, 20-triol
- Beagle dog
- Erythrocyte count, RBC
- Ginsenoside
- SPSS, statistical package for social sciences
- Subchronic toxicity
- alanine aminotransferase, ALT
- albumin, ALB
- alkaline phosphatase, ALP
- aspartate aminotransferase, AST
- basophils, BASO
- chloride, Cl
- creatine phosphokinase, CK
- creatinine, Crea
- eosinophils, EOS
- gamma-glutamyl transferase, γ-GT
- glucose, GLU
- hematocrit, HCT
- hemoglobin concentration distribution width, HDW
- hemoglobin concentration, HGB
- lymphocytes, LYMPH
- mean corpuscular hemoglobin concentration, MCHC
- mean corpuscular hemoglobin, MCH
- mean corpuscular volume, MCV
- mean platelet volume, MPV
- micronucleated polychromatic erythrocytes, MNPCE
- monocytes, MONO
- neutrophil cell, NEUT
- normochromatic erythrocytes, NCE
- platelets, PLT
- polychromatic erythrocytes, PCE
- potassium, K
- prothrombin time, PT
- red cell distribution width, RDW%
- reticulocyte count, RETIC
- sodium, Na
- total bilirubin, T.BIL
- total calcium, TCa
- total cholesterol, T.CHO
- total protein, T.P
- total triglyceride, TG
- urea nitrogen, BUN
- white blood cells count, WBC
Collapse
Affiliation(s)
- Wei Li
- Department of Functional Food and Wine, Shenyang pharmaceutical University, Shenyang, China
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang, China
| | - Xiangrong Zhang
- Department of Functional Food and Wine, Shenyang pharmaceutical University, Shenyang, China
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang, China
| | - Meng Ding
- Department of Functional Food and Wine, Shenyang pharmaceutical University, Shenyang, China
| | - Yanfei Xin
- Center of Safety Evaluation, Zhejiang Academy of Medical Sciences, Hangzhou, China
| | - Yaoxian Xuan
- Center of Safety Evaluation, Zhejiang Academy of Medical Sciences, Hangzhou, China
| | - Yuqing Zhao
- Department of Functional Food and Wine, Shenyang pharmaceutical University, Shenyang, China
- Key Laboratory of Structure-Based Drug Design & Discovery of Ministry of Education, Shenyang, China
- Corresponding author. Department of Functional Food and Wine, Shenyang Pharmaceutical University, Shenyang, 110016, China.
| |
Collapse
|
3
|
Philips CA, Phadke N, Ganesan K, Rajesh S, Padsalgi G, Ahamed R, John SK, Valiathan GC, Augustine P. Gut Microbiota in Alcoholic Hepatitis is Disparate from Those in Acute Alcoholic Pancreatitis and Biliary Disease. J Clin Exp Hepatol 2019; 9:690-698. [PMID: 31889749 PMCID: PMC6926215 DOI: 10.1016/j.jceh.2019.04.001] [Citation(s) in RCA: 6] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2018] [Accepted: 04/03/2019] [Indexed: 02/07/2023] Open
Abstract
BACKGROUND Alcoholic hepatitis (AH) is associated with gut dysbiosis. Comparative gut microbial profiles of acute alcoholic pancreatitis (AAP) and acute biliary disease (ABD) are not demonstrated. We aimed to compare gut microbiota of AH, AAP, and ABD patients with each other and with their respective healthy controls (HCs). METHODS From December 2016 to September 2017, consecutive patients with AH, AAP, and ABD (acute cholecystitis, acute biliary pancreatitis, and choledocholithiasis with cholangitis) were included in the study. Qualitative and functional stool microbiota comparative analysis was performed between groups, with AH as the reference comparator. RESULTS Of 3564, 882, and 224 patients with liver disease, pancreatic disease, and biliary disease, respectively, after exclusion, 29 patients with AH and 7 patients each with AAP and ABD and their corresponding HCs were included in the study analysis. The alpha diversity between patients with AH and AAP was found to be significantly different. Significant relative abundance (RA) of Acinetobacter and Moraxella was noted among patients with AAP. Enterobacter, Atopobium, Synergistia, and Devosia were significantly higher in patients with ABD compared to patients with AH, in whom Faecalibacterium and Megamonas were higher. Functional pathways associated with carbohydrate metabolism, phenylpropanoid biosynthesis, and ethylbenzene degradation were significantly higher in AAP when compared to AH. Fatty acid and inositol phosphate metabolism and dioxin degradation were significantly upregulated in patients with ABD while lipid and fatty acid biosynthetic pathways and pathways associated with immune processes were upregulated in patients with AH. CONCLUSIONS Differential gut dysbiosis is evident in both patients with AH, AAP, and ABD and also in comparison to HCs. The differential microbiota among patients with AH and AAP maybe important in promotion and progression of liver or pancreatic disease among alcohol users and may be a potential therapeutic target, which needs to be confirmed in larger multicenter studies.
Collapse
Key Words
- Bedside Index of Severity in Acute Pancreatitis, BISAP
- Kyoto Encyclopedia of Genes and Genomes, KEGG
- Phylogenetic Investigation of Communities by Reconstruction of Unobserved States, PICRUSt
- Principal coordinate analysis, PcoA
- Quantitative Insights into Microbial Ecology, QIIME
- acute alcoholic pancreatitis, AAP
- acute biliary disease, ABD
- alanine aminotransferase, ALT
- alcoholic hepatitis
- alcoholic hepatitis, AH
- alcoholic liver disease, ALD
- aspartate aminotransferase, AST
- chronic alcoholic pancreatitis, CAP
- computed tomography, CT
- dysbiosis
- healthy controls, HC
- linear discriminant analysis effect size, LEfSe
- metagenomics
- microbiota
- pancreatitis
Collapse
Affiliation(s)
- Cyriac A. Philips
- Gastroenterology and the Liver Unit, Cochin Gastroenterology Group, Ernakulam Medical Centre, Kochi, Kerala, India,Address for correspondence: Cyriac A. Philips, MD DM, Philip Augustine Associates. 35/194 B, Symphony, Automobile Rd., Palarivattom, Kochi, Kerala, 682025, India. Tel.: +91 9207745776.
| | - Nikhil Phadke
- Molecular, Cellular and Developmental Biology, Genepath-Dx, Pune, Maharashtra, India
| | | | - Sasidharan Rajesh
- Gastroenterology and the Liver Unit, Cochin Gastroenterology Group, Ernakulam Medical Centre, Kochi, Kerala, India
| | - Guruprasad Padsalgi
- Gastroenterology and the Liver Unit, Cochin Gastroenterology Group, Ernakulam Medical Centre, Kochi, Kerala, India
| | - Rizwan Ahamed
- Gastroenterology and the Liver Unit, Cochin Gastroenterology Group, Ernakulam Medical Centre, Kochi, Kerala, India
| | - Solomon K. John
- Hepatobiliary and Transplant Surgery, Cochin Gastroenterology Group, Ernakulam Medical Centre, Kochi, Kerala, India
| | - Gopakumar C. Valiathan
- Hepatobiliary and Transplant Surgery, Cochin Gastroenterology Group, Ernakulam Medical Centre, Kochi, Kerala, India
| | - Philip Augustine
- Gastroenterology and the Liver Unit, Cochin Gastroenterology Group, Ernakulam Medical Centre, Kochi, Kerala, India
| |
Collapse
|